Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
42 JPY
243.25 M JPY
1.35 B JPY
4.21 M
About HUMAN METABOLOME TECHNOLOGIES INC
Sector
Industry
Headquarters
Tsuruoka
Website
Founded
2003
ISIN
JP3794530000
FIGI
BBG005MQ74F4
Human Metabolome Technologies, Inc. engages in the business of diagnostic technology and medical products. Its operations are carried out through the following segments: Metabolome Analysis, Biomarker, and Temporary Staffing. The Metabolome Analysis segment provides contract analysis service based on the metabolome analysis on measured samples from the clients. The Biomarker segment deals with the development of biomarker license in collaboration with the group companies. The Temporary Staffing segment provides researchers and technicians. The company was founded by Yoshihiro Otaki, Masaru Tomita, and Tomoyoshi Soga on July 1, 2003 and is headquartered in Tsuruoka, Japan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 6090 is 602 JPY — it has decreased by −0.33% in the past 24 hours. Watch HUMAN METABOLOME TECHNOLOGIES INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange HUMAN METABOLOME TECHNOLOGIES INC stocks are traded under the ticker 6090.
6090 stock has risen by 2.56% compared to the previous week, the month change is a 3.79% rise, over the last year HUMAN METABOLOME TECHNOLOGIES INC has showed a −10.81% decrease.
6090 reached its all-time high on Jan 6, 2014 with the price of 5,920 JPY, and its all-time low was 453 JPY and was reached on Mar 13, 2020. View more price dynamics on 6090 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
6090 stock is 1.33% volatile and has beta coefficient of 0.41. Track HUMAN METABOLOME TECHNOLOGIES INC stock price on the chart and check out the list of the most volatile stocks — is HUMAN METABOLOME TECHNOLOGIES INC there?
Today HUMAN METABOLOME TECHNOLOGIES INC has the market capitalization of 3.56 B, it has increased by 2.90% over the last week.
Yes, you can track HUMAN METABOLOME TECHNOLOGIES INC financials in yearly and quarterly reports right on TradingView.
HUMAN METABOLOME TECHNOLOGIES INC is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
6090 net income for the last quarter is −35.42 M JPY, while the quarter before that showed 14.69 M JPY of net income which accounts for −341.19% change. Track more HUMAN METABOLOME TECHNOLOGIES INC financial stats to get the full picture.
HUMAN METABOLOME TECHNOLOGIES INC dividend yield was 2.37% in 2024, and payout ratio reached 36.46%. The year before the numbers were 1.34% and 20.66% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 23, 2024, the company has 58.00 employees. See our rating of the largest employees — is HUMAN METABOLOME TECHNOLOGIES INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HUMAN METABOLOME TECHNOLOGIES INC EBITDA is 334.39 M JPY, and current EBITDA margin is 22.78%. See more stats in HUMAN METABOLOME TECHNOLOGIES INC financial statements.
Like other stocks, 6090 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HUMAN METABOLOME TECHNOLOGIES INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HUMAN METABOLOME TECHNOLOGIES INC technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HUMAN METABOLOME TECHNOLOGIES INC stock shows the sell signal. See more of HUMAN METABOLOME TECHNOLOGIES INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.